Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective—: Increased body iron stores and hepcidin have been hypothesized to promote atherosclerosis by inducing macrophage iron accumulation and release of cytokines, but direct demonstration in human cells is lacking. The aim of this study was to evaluate the effect of iron on cytokine release in monocytes ex vivo and the correlation with vascular damage and to evaluate the relationship among serum levels of hepcidin, cytokines, and vascular damage in patients with metabolic syndrome alterations. Methods and Results—: Manipulation of iron status with ferric ammonium citrate and hepcidin-25 induced monocyte chemoattractant protein (MCP)-1 and interleukin-6 in human differentiating monocytes of patients with hyperferritinemia associated with the metabolic syndrome (n=11), but not in subjects with hemochromatosis or HFE mutations impairing iron accumulation (n=15), and the degree of induction correlated with the presence of carotid plaques, detected by echocolor–Doppler. In monocytes of healthy subjects (n=7), iron and hepcidin increased the mRNA levels and release of MCP-1, but not of interleukin-6. In 130 patients with metabolic alterations, MCP-1 levels, as detected by ELISA, were correlated with hepcidin-25 measured by time-of-flight mass spectrometry ( P =0.005) and were an independent predictor of the presence of carotid plaques ( P =0.05). Conclusion—: Hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in high-risk individuals with metabolic alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Bekri, S., Gual, P., Anty, R., Luciani, N., Dahman, M., Ramesh, B., Iannelli, A., Staccini–Myx, A., Casanova, D., Ben Amor, I., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.007 · Cited by 496
Autocrine formation of hepcidin induces iron retention in human monocytes
Theurl, I., Theurl, M., Seifert, M., Mair, S., Nairz, M., Rumpold, H., Zoller, H., Bellmann-Weiler, R., Niederegger, H., Talasz, H., et al. (2008) · Blood · doi:10.1182/blood-2007-05-090019 · Cited by 275 · cited 1×
“Metabolic syndrome 9 (82) 7 (78) 1 (17)”
Iron Chelation Improves Endothelial Function in Patients With Coronary Artery Disease
Duffy, S. J., Biegelsen, E. S., Holbrook, M., Russell, J. D., Gokce, N., Keaney, J. F., & Vita, J. A. (2001) · Circulation · doi:10.1161/01.cir.103.23.2799 · Cited by 271
Hemochromatosis: An endocrine liver disease
Pietrangelo, A. (2007) · Hepatology · doi:10.1002/hep.21886 · Cited by 212
Chronic Iron Administration Increases Vascular Oxidative Stress and Accelerates Arterial Thrombosis
Day, S. M., Duquaine, D., Mundada, L. V., Menon, R. G., Khan, B. V., Rajagopalan, S., & Fay, W. P. (2003) · Circulation · doi:10.1161/01.cir.0000066910.02844.d0 · Cited by 192
Iron-Deficient Diet Reduces Atherosclerotic Lesions in ApoE-Deficient Mice
Lee, T.-S., Shiao, M.-S., Pan, C.-C., & Chau, L.-Y. (1999) · Circulation · doi:10.1161/01.cir.99.9.1222 · Cited by 179
Wang, L., Johnson, E. E., Shi, H. N., Walker, W. A., Wessling-Resnick, M., & Cherayil, B. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2723 · Cited by 159
Cairo, G., Recalcati, S., Montosi, G., Castrusini, E., Conte, D., & Pietrangelo, A. (1997) · Blood · doi:10.1182/blood.v89.7.2546 · Cited by 96
Cited by
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667
Macdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 482
Self-citationIron in fatty liver and in the metabolic syndrome: A promising therapeutic target
Dongiovanni, P., Fracanzani, A. L., Fargion, S., & Valenti, L. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.008 · Cited by 362
Self-citationThe multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 275
Self-citationEffects of iron overload on chronic metabolic diseases
Fernández-Real, J. M., & Manco, M. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70174-8 · Cited by 265
Hepcidin in Human Iron Disorders: Diagnostic Implications
Kroot, J. J., Tjalsma, H., Fleming, R. E., & Swinkels, D. W. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2009.140053 · Cited by 246
Self-citation“Pumping iron”—how macrophages handle iron at the systemic, microenvironmental, and cellular levels
Nairz, M., Theurl, I., Swirski, F. K., & Weiss, G. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-1944-8 · Cited by 178
The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes
Zughaier, S. M., Alvarez, J. A., Sloan, J. H., Konrad, R. J., & Tangpricha, V. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2014.01.003 · Cited by 174
Metadata
- Authors
- Valenti, L., Dongiovanni, P., Motta, B. M., Swinkels, D. W., Bonara, P., Rametta, R., Burdick, L., Frugoni, C., Fracanzani, A. L., & Fargion, S.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2011-03
- Volume
- 31
- Issue
- 3
- Pages
- 683-690
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W1977387211
- Cited by
- 89
- References
- 10
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.